| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199409083311001 |
| P698 | PubMed publication ID | 8052271 |
| P50 | author | Paul W. Fedak | Q42732504 |
| P2093 | author name string | Kelton JG | |
| Singer J | |||
| Richards C | |||
| Walker I | |||
| Heddle NM | |||
| Klama L | |||
| Fedak P | |||
| P2860 | cites work | Production of hybridoma growth factor by human monocytes. | Q52827130 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 625-628 | |
| P577 | publication date | 1994-09-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | The role of the plasma from platelet concentrates in transfusion reactions | |
| P478 | volume | 331 |
| Q46419179 | A case-control study of the impact of WBC reduction on the cost of hospital care for patients undergoing coronary artery bypass graft surgery |
| Q38204784 | A comparison of adverse reaction rates for PAS C versus plasma platelet units |
| Q50446033 | A hollow-fibre column system to effectively prepare washed platelets. |
| Q40424356 | A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment |
| Q40579927 | A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets |
| Q24801336 | A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440] |
| Q24186913 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q44059748 | Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial |
| Q35792449 | Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? |
| Q33362738 | Acute lung injury after blood transfusion in mechanically ventilated patients |
| Q50526083 | Adhesive interaction between peripheral blood mononuclear cells and activated platelets in the presence of anti-human leukocyte antigen Class I alloantibody causes production of IL-1β and IL-8. |
| Q40646670 | Allogeneic blood transfusion and postoperative duration of mechanical ventilation: effects of red cell supernatant, platelet supernatant, plasma components and total transfused fluid |
| Q56794926 | Altering interface detector positioning in combination with prestorage filtration to achieve a better quality of single donor platelet concentrates using the CS 3000 plus blood separator |
| Q40427955 | An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment |
| Q40594585 | Analysis of 516 reports of reactions after the transfusion of labile blood products |
| Q71703913 | Analysis of P50 and oxygen transport in patients after cardiac surgery |
| Q40640145 | Analysis of transfusion incident reports filed at 15 blood transfusion centers and health facilities during 17 months. Groupe Receveurs de laSFTS |
| Q33402235 | Anaphylactic transfusion reaction in a patient with anhaptoglobinemia: the first case in Korea |
| Q33408363 | Approach of using established and new laboratory tests to more comprehensively investigate noninfectious and nonhemolytic transfusion reactions--along with the experience in Japan |
| Q33579626 | Are cytokines in platelet concentrates responsible for febrile transfusion reactions? |
| Q63753676 | Bioactive substance accumulation and septic complications in a burn trauma patient: effect of perioperative blood transfusion? |
| Q42701728 | Blood transfusions and human recombinant erythropoietin in premature newborn infants |
| Q40243803 | Blood transfusions and pulmonary complications after hematopoietic cell transplantation |
| Q37429101 | CD40 ligand (CD154) involvement in platelet transfusion reactions |
| Q47686840 | Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. |
| Q42522894 | Characterization and functional analysis of granulocyte concentrates collected from donors after repeated G-CSF stimulation |
| Q33369694 | Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial |
| Q33401230 | Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis |
| Q50506735 | Comparative in vitro evaluation of apheresis platelets stored with 100% plasma versus bicarbonated Ringer's solution with less than 5% plasma. |
| Q24187751 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q47885519 | Complement activation in prestorage leucocyte-filtered plasma |
| Q52866928 | Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. |
| Q33769745 | Considerations in the selection of a platelet component: apheresis versus whole blood-derived |
| Q39506366 | Correlation of cytokine elaboration with mononuclear cell adhesion to platelet storage bag plastic polymers: a pilot study |
| Q44553130 | Costs and benefits of PAS platelets: a mix of science, quality, and value |
| Q33560053 | Current concepts in platelet transfusion |
| Q40607408 | Current issues in platelet transfusion therapy |
| Q33332595 | Current issues with platelet transfusion in patients with cancer |
| Q26996247 | Current methods for the reduction of blood-borne pathogens: a comprehensive literature review |
| Q83314815 | Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage |
| Q74107507 | Cytokine accumulation in stored red cell concentrates: effect of buffy-coat removal and leucoreduction |
| Q40584632 | Cytokine release in febrile non-haemolytic red cell transfusion reactions |
| Q37398709 | Difference in autologous blood transfusion-induced inflammatory responses between acute normovolemic hemodilution and preoperative donation |
| Q24186359 | Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q40277127 | Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets |
| Q41789969 | Evaluation of White Blood Cell- and Platelet-Derived Cytokine Accumulation in MIRASOL-PRT-Treated Platelets |
| Q43030511 | Evaluation of a red cell leukofilter performance and effect of buffy coat removal on filtration efficiency and post filtration storage |
| Q40547941 | Evaluation of adherence to the regulations for declaration of notification of transfusion reactions with fever and chills. A study of the Association Inter-Régionale du Sud-Est d'Hémovigilance (AIRSEH) |
| Q36340230 | Evaluation of transfusion pyrexia: a review of differential diagnosis and management |
| Q34405086 | Evidence-based recommendations for the use of WBC-reduced cellular blood components |
| Q37464134 | Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS). |
| Q90158335 | Extracellular DNA in blood products and its potential effects on transfusion |
| Q47385021 | Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial |
| Q40628811 | Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations |
| Q47552365 | From cytokines to pragmatic designs: changing paradigms |
| Q50551784 | Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions. |
| Q33336925 | Haemopoietic growth factors in paediatric oncology: a review of the literature |
| Q50701346 | Heavy breathing in the blood bank: is it transfusion-related acute lung injury, our anxiety, or both? |
| Q91936201 | Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice |
| Q46885219 | In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution |
| Q44036356 | In vitro safety profile of G-CSF-mobilized whole blood after storage for 7 days in an infusable-grade L15 medium |
| Q50451821 | In vitro variables of buffy coat-derived platelet concentrates with residual plasma of down to 10% are stably maintained in new-generation platelet additive solutions. |
| Q35131632 | In vivo and in vitro comparison of platelets stored in either synthetic media or plasma |
| Q34154813 | Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation |
| Q30328537 | Inactivation of infectious pathogens in labile blood components: meeting the challenge. |
| Q30431256 | Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates |
| Q77925242 | Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives |
| Q33953454 | Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis |
| Q37776316 | Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION |
| Q41210322 | Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? |
| Q33407359 | Inverse probability weighted estimating equations for randomized trials in transfusion medicine |
| Q48386621 | Jack A. Barney Resident Research Award winner. The inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure |
| Q34022474 | Leucocyte depletion of the blood supply - how will patients benefit? |
| Q73069624 | Leukocyte depletion and storage of single-donor platelet concentrates |
| Q33835138 | Leukocyte reduction of blood components: public policy and new technology |
| Q37440904 | Microarray kit analysis of cytokines in blood product units and segments |
| Q50658148 | Neutrophil function is preserved in a pooled granulocyte component prepared from whole blood donations. |
| Q38604097 | New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells |
| Q33380368 | Novel thrombopoetin mimetic agents with potential to ameliorate chemotherapy-induced thrombocytopenia |
| Q33361167 | Optimizing platelet transfusion therapy |
| Q45030789 | Parallel comparison of apheresis-collected platelet concentrates stored in four different additive solutions |
| Q35095646 | Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ |
| Q45136674 | Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products |
| Q33396720 | Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study |
| Q33383425 | Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans. |
| Q34279813 | Pilot analysis of cytokines levels in stored granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell concentrates |
| Q37380265 | Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. |
| Q73288183 | Plasma and lipids from stored platelets cause acute lung injury in an animal model |
| Q43662394 | Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion |
| Q50521947 | Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. |
| Q43706324 | Platelet immunology and the immune response |
| Q38015853 | Platelet storage and transfusions: new concerns associated with an old therapy |
| Q42143205 | Platelet storage lesion: An update |
| Q38362628 | Platelet transfusion - the new immunology of an old therapy |
| Q71919358 | Platelet transfusion therapy |
| Q33488344 | Platelet transfusion therapy in newborn infants |
| Q90422944 | Platelet transfusion: Current challenges |
| Q56505470 | Platelet transfusions |
| Q40577692 | Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction |
| Q34708937 | Platelet transfusions: Impact on hemostasis, thrombosis, inflammation and clinical outcomes |
| Q38017397 | Platelets and cytokines: How and why? |
| Q40613596 | Platelets expressing P-selectin and platelet-derived microparticles in stored platelet concentrates bind to PSGL-1 on filtrated leukocytes |
| Q53994525 | Platelets stored in a glucose-free additive solution or in autologous plasma--an ultrastructural and morphometric evaluation. |
| Q63753633 | Prestorage leukocyte filtration may reduce leukocyte-derived bioactive substance accumulation in patients operated for burn trauma |
| Q33835135 | Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion |
| Q73821776 | Prevention of monocyte adhesion and inflammatory cytokine production during blood platelet storage: an in vitro model with implications for transfusion practice |
| Q48112813 | Prolonged platelet storage associated with increased frequency of transfusion-related adverse events |
| Q24197779 | Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation |
| Q40607411 | Quality of platelet components: the role of suspension medium and leukocyte depletion |
| Q33395008 | Reactions Induced by Platelet Transfusions |
| Q38023134 | Recent advances toward defining the benefits and risks of erythrocyte transfusions in neonates |
| Q33417573 | Recurrent life-threatening reactions to platelet transfusion in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone |
| Q44023975 | Reducing the financial impact of pathogen inactivation technology for platelet components: our experience |
| Q91166763 | Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan-A retrospective multicenter study |
| Q40709312 | Reduction of bacteria and human immunodeficiency virus Type 1 infectivity of platelet suspension in plasma using xenon flash-pulse light in a bench-scale trial |
| Q40543308 | Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction |
| Q41114243 | Risk management in transfusion medicine |
| Q33328995 | Risks, costs, and alternatives to platelet transfusions |
| Q34564946 | Signs and symptoms associated with the transfusion of WBC-reduced RBCs and non-WBC-reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study |
| Q79095562 | Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, β‐thromboglobulin, platelet factor 4 and interleukin‐7, during storage |
| Q50448800 | The IgE-dependent pathway in allergic transfusion reactions: involvement of donor blood allergens other than plasma proteins. |
| Q39078020 | The association of fever with transfusion-associated circulatory overload. |
| Q44366010 | The effect of plasma depletion of platelet concentrates on platelet aggregation and phosphatidylserine expression |
| Q50494182 | The effect of pre-storage whole-blood leukocyte reduction on cytokines/chemokines levels in autologous CPDA-1 whole blood. |
| Q34192814 | The immunocompromised patient and transfusion |
| Q38430799 | The impact of two different transfusion strategies on patient immune response during major abdominal surgery: a preliminary report |
| Q78833819 | The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage |
| Q35184743 | The quality of platelets after storage for 7 days |
| Q33579652 | The red cell storage lesion and its implication for transfusion |
| Q40426156 | The role of cytokines in blood transfusion reactions |
| Q33496297 | The thrombocytopenia of cancer. Prospects for effective cytokine therapy |
| Q35813075 | The top ten list of randomized controlled trials in transfusion medicine |
| Q40622971 | The utility of < or =3-day-old whole-blood platelets in reducing the incidence of febrile nonhemolytic transfusion reactions |
| Q33361940 | Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution |
| Q53584513 | Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction--a phase I clinical trial. |
| Q40945066 | Transfusion and stem cell support in cancer treatment |
| Q77925237 | Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8 |
| Q36831189 | Transfusion premedications: a growing practice not based on evidence |
| Q44219668 | Transfusion reactions: a comparative observational study of blood components produced before and after implementation of semiautomated production from whole blood |
| Q50053079 | Transfusion-associated adverse reactions (TAARs) and cytokine accumulations in the stored blood components: the impact of prestorage versus poststorage leukoreduction |
| Q28255426 | Transfusion-related acute lung injury |
| Q36546623 | Transfusion-related acute lung injury: a literature review |
| Q27346544 | Transfusion-related adverse events in the Platelet Dose study |
| Q41825858 | Transfusion-related adverse reactions in pediatric and surgical patients at a tertiary care teaching hospital in India |
| Q52853542 | Treatment of platelet concentrates with ultraviolet C light for pathogen reduction increases cytokine accumulation. |
| Q38113482 | Umbilical cord blood transplantation: review of factors affecting the hospitalized patient |
| Q34247853 | Universal WBC reduction: the case for and against |
| Q78859732 | WBC reduction reduces storage-associated RBC adhesion to human vascular endothelial cells under conditions of continuous flow in vitro |
| Q37671773 | Why implement universal leukoreduction? |
| Q80375194 | [Bacterial contamination: should it be detected or inactivated?] |
| Q81798895 | [Haemovigilance: state 1995-2003 Casablanca] |
| Q72279717 | [Indications and surveillance of platelet transfusions in surgery] |
| Q53791119 | [Platelet transfusion and allergic transfusion reactions: experiences at Lille Hospital over a four year period] |
| Q64960314 | [Platelets cytokines and their effects on platelet transfusion]. |
| Q81839369 | [Progress in transfusion for storage of platelets] |
Search more.